These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 17362522

  • 1. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
    Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC.
    Radiat Oncol; 2007 Mar 15; 2():13. PubMed ID: 17362522
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
    Murray L, Sethugavalar B, Robertshaw H, Bayman E, Thomas E, Gilson D, Prestwich RJ.
    Clin Oncol (R Coll Radiol); 2015 Jul 15; 27(7):401-10. PubMed ID: 25840609
    [Abstract] [Full Text] [Related]

  • 6. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
    Chera BS, Rodriguez C, Morris CG, Louis D, Yeung D, Li Z, Mendenhall NP.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):1173-80. PubMed ID: 19386423
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 8. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.
    J Clin Oncol; 2010 Sep 20; 28(27):4199-206. PubMed ID: 20713848
    [Abstract] [Full Text] [Related]

  • 9. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
    Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Mueller RP, Wenz F, Eich HT.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):268-76. PubMed ID: 22079733
    [Abstract] [Full Text] [Related]

  • 10. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
    Maraldo MV, Jørgensen M, Brodin NP, Aznar MC, Vogelius IR, Petersen PM, Berthelsen AK, Christensen CB, Hjalgrim LL, Specht L.
    Pediatr Blood Cancer; 2014 Apr 01; 61(4):717-22. PubMed ID: 24660228
    [Abstract] [Full Text] [Related]

  • 11. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
    De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE.
    J Clin Oncol; 2009 Sep 10; 27(26):4239-46. PubMed ID: 19667275
    [Abstract] [Full Text] [Related]

  • 12. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma.
    Jørgensen AY, Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Rosenschöld PM, Petersen PM, Specht L.
    Acta Oncol; 2013 Oct 10; 52(7):1559-65. PubMed ID: 24047340
    [Abstract] [Full Text] [Related]

  • 13. Late effects in the era of modern therapy for Hodgkin lymphoma.
    Hodgson DC.
    Hematology Am Soc Hematol Educ Program; 2011 Oct 10; 2011():323-9. PubMed ID: 22160053
    [Abstract] [Full Text] [Related]

  • 14. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
    Mazonakis M, Lyraraki E, Damilakis J.
    Med Phys; 2017 Jul 10; 44(7):3866-3874. PubMed ID: 28493609
    [Abstract] [Full Text] [Related]

  • 15. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
    Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, Lynch J, Li Z, Mendenhall NP.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):260-7. PubMed ID: 22014950
    [Abstract] [Full Text] [Related]

  • 16. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN, Li YX, Wu RY, Zhang XM, Wang WH, Jin J, Song YW, Fang H, Ren H, Wang SL, Liu YP, Liu XF, Chen B, Dai JR, Yu ZH.
    Int J Radiat Oncol Biol Phys; 2012 Sep 01; 84(1):210-6. PubMed ID: 22436783
    [Abstract] [Full Text] [Related]

  • 17. [Radiotherapy in adults with localized supradiaphragmatic stages CS I/II of Hodgkin's disease. 2. The special aspects of radiotherapy: dosage, fractionation, focal volumes, risks, conclusions].
    Glanzmann C, Lütolf UM.
    Strahlenther Onkol; 1993 Oct 01; 169(10):570-83. PubMed ID: 8235981
    [Abstract] [Full Text] [Related]

  • 18. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Dühmke E, Diehl V, Müller RP.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):860-5. PubMed ID: 15925455
    [Abstract] [Full Text] [Related]

  • 19. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
    Kahn S, Flowers C, Xu Z, Esiashvili N.
    Int J Radiat Oncol Biol Phys; 2011 Sep 01; 81(1):175-80. PubMed ID: 20732769
    [Abstract] [Full Text] [Related]

  • 20. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
    Maraldo MV, Brodin P, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L.
    Int J Radiat Oncol Biol Phys; 2013 Oct 01; 87(2):297-303. PubMed ID: 23910709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.